WO1996016079A3 - Alpha-ketoamide derivatives as cathepsin l inhibitor - Google Patents

Alpha-ketoamide derivatives as cathepsin l inhibitor Download PDF

Info

Publication number
WO1996016079A3
WO1996016079A3 PCT/JP1995/002389 JP9502389W WO9616079A3 WO 1996016079 A3 WO1996016079 A3 WO 1996016079A3 JP 9502389 W JP9502389 W JP 9502389W WO 9616079 A3 WO9616079 A3 WO 9616079A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
cathepsin
inhibitor
group
alpha
Prior art date
Application number
PCT/JP1995/002389
Other languages
French (fr)
Other versions
WO1996016079A2 (en
Inventor
Takashi Sohda
Yukio Fujisawa
Tsuneo Yasuma
Junji Mizoguchi
Original Assignee
Takeda Chemical Industries Ltd
Takashi Sohda
Yukio Fujisawa
Tsuneo Yasuma
Junji Mizoguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Takashi Sohda, Yukio Fujisawa, Tsuneo Yasuma, Junji Mizoguchi filed Critical Takeda Chemical Industries Ltd
Priority to CA002200964A priority Critical patent/CA2200964A1/en
Priority to AU39358/95A priority patent/AU3935895A/en
Priority to EP95937173A priority patent/EP0793673A1/en
Publication of WO1996016079A2 publication Critical patent/WO1996016079A2/en
Publication of WO1996016079A3 publication Critical patent/WO1996016079A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a cathepsin L inhibitor comprising a compound of general formula (Ia), wherein Q represents a direct bond or 1 or 2 amino acid residues that may be substituted; R1 represents a hydrogen atom or a hydrocarbon group or heterocyclic group that may be substituted; R4 represents an acyl group or a carboxyl group that may be esterified and R?5 and R6¿ independently represent a hydrogen atom or a hydrocarbon group or heterocyclic group that may be substituted or R?5 and R6¿ may bind together to form a ring; or a salt thereof, which has strong bone resorption-suppressing action and is useful for preventing or treating osteoporosis.
PCT/JP1995/002389 1994-11-24 1995-11-24 Alpha-ketoamide derivatives as cathepsin l inhibitor WO1996016079A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002200964A CA2200964A1 (en) 1994-11-24 1995-11-24 Alpha-ketoamide derivatives as cathepsin l inhibitor
AU39358/95A AU3935895A (en) 1994-11-24 1995-11-24 Alpha-ketoamide derivatives as cathepsin l inhibitor
EP95937173A EP0793673A1 (en) 1994-11-24 1995-11-24 Alpha-ketoamide derivatives as cathepsin l inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6/290132 1994-11-24
JP29013294 1994-11-24

Publications (2)

Publication Number Publication Date
WO1996016079A2 WO1996016079A2 (en) 1996-05-30
WO1996016079A3 true WO1996016079A3 (en) 1996-09-12

Family

ID=17752214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/002389 WO1996016079A2 (en) 1994-11-24 1995-11-24 Alpha-ketoamide derivatives as cathepsin l inhibitor

Country Status (4)

Country Link
EP (1) EP0793673A1 (en)
AU (1) AU3935895A (en)
CA (1) CA2200964A1 (en)
WO (1) WO1996016079A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2959397A (en) * 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6150378A (en) * 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
AU2055301A (en) * 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
US6703513B1 (en) 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
WO2002002546A1 (en) 2000-06-30 2002-01-10 Seikagaku Corporation EPOXYCARBOXYLIC ACID AMIDES, AZIDES AND AMINO ALCOHOLS AND PROCESSES FOR PREPARATION OF α-KETO AMIDES BY USING THEM
US20050107616A1 (en) * 2001-08-03 2005-05-19 David Gene Barrett Alpha-ketoamide derivatives as cathepsin k inhibitors
WO2003062192A1 (en) * 2002-01-17 2003-07-31 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
JP2005532290A (en) * 2002-04-10 2005-10-27 スミスクライン ビーチャム コーポレーション 1- (Oxoaminoacetyl) pentylcarbamate derivatives as cathepsin K inhibitors for treating bone loss
US7022738B2 (en) 2002-07-22 2006-04-04 Senju Pharmaceutical Co., Ltd. α-ketoamide derivative and use thereof
JP5666468B2 (en) * 2008-12-19 2015-02-12 メディヴィル・ユーケイ・リミテッド Cysteine protease inhibitor
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
EP2633855A1 (en) 2012-03-01 2013-09-04 Veterinärmedizinische Universität Wien Protease inhibitors for treating Trichomonas gallinae infections
CA2914178C (en) 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
US9765099B2 (en) 2013-05-08 2017-09-19 Board Of Regents, The University Of Texas System STAT6 inhibitors
US10570100B2 (en) 2015-07-08 2020-02-25 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10577321B2 (en) 2015-07-08 2020-03-03 University Of Southern California Deoxyuridine triphosphatase inhibitors
US10570098B2 (en) 2015-07-08 2020-02-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
DK3464336T3 (en) 2016-06-01 2022-05-09 Athira Pharma Inc CONNECTIONS
MX2018016189A (en) 2016-06-21 2019-06-10 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives.
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098209A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
WO2018098208A1 (en) * 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468339A2 (en) * 1990-07-27 1992-01-29 Nippon Kayaku Kabushiki Kaisha Alpha-keto-amide derivatives having protease inhibiting activity
WO1992011850A2 (en) * 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
WO1992012140A1 (en) * 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
WO1994000095A2 (en) * 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
WO1994008941A1 (en) * 1992-10-16 1994-04-28 Corvas International, Inc. Arginine keto-amide enzyme inhibitors
EP0603769A1 (en) * 1992-12-25 1994-06-29 Mitsubishi Chemical Corporation Alpha-Aminoketone derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468339A2 (en) * 1990-07-27 1992-01-29 Nippon Kayaku Kabushiki Kaisha Alpha-keto-amide derivatives having protease inhibiting activity
WO1992011850A2 (en) * 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
WO1992012140A1 (en) * 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
WO1994000095A2 (en) * 1992-06-24 1994-01-06 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
WO1994008941A1 (en) * 1992-10-16 1994-04-28 Corvas International, Inc. Arginine keto-amide enzyme inhibitors
EP0603769A1 (en) * 1992-12-25 1994-06-29 Mitsubishi Chemical Corporation Alpha-Aminoketone derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESSER, R.E. ET AL.: "Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis", ARTHRITIS & RHEUMATISM, vol. 37, no. 2, 1 February 1994 (1994-02-01), pages 236 - 247, XP000566128 *
LI, Z. ET AL.: "Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other csyteine proteases", J. MED. CHEM., vol. 36, 1993, pages 3472 - 3480, XP000565670 *

Also Published As

Publication number Publication date
EP0793673A1 (en) 1997-09-10
WO1996016079A2 (en) 1996-05-30
AU3935895A (en) 1996-06-17
CA2200964A1 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
WO1996016079A3 (en) Alpha-ketoamide derivatives as cathepsin l inhibitor
US5889009C1 (en) Method of inhibiting cell adhesion
BG103485A (en) Ketobanzamides as calpain inhibitors
ES2052452A1 (en) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
HK1006711A1 (en) Substituted heterocyclic carboxylic acid amides their preparation and their use as medicaments
NZ247642A (en) Thioalkylacyl substituted heterocyclic compounds; pharmaceutical compositions and preparatory methods
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
CA2110693A1 (en) Amino acid derivative anticonvulsant
ATE227293T1 (en) 2,3-DISUBSTITUTED-(5,6)-HETEROARYL CONDENSED - PYRIMIDINE-4-ONE
IE811582L (en) Amide derivatives.
EP0296581A3 (en) Amino acid 1,2-diketo derivatives as renin inhibitors
IL136100A (en) Biphenylamidine derivatives and pharmaceutical compositions containing the same
GR3036836T3 (en) Sulfur-containing heterocyclic compounds.
AU2223595A (en) Aziridine derivatives, their production and use
DE69429642D1 (en) Lactol derivatives, as cathepsin L inhibitors
AU1198897A (en) 1-benzenesulfonyl pyrrolidine derivatives as bradykinin receptor antagonists
WO1997031016A3 (en) New inhibitors of sh2-mediated processes
GR3034615T3 (en) Aminophenylalanine derivatives, process for their production, their use and agents containing them as anti-coagulants.
PL310655A1 (en) Derivatives of hydroxymethylfurasane carboxylic acid and their application in treating cardiovascular diseases
WO2001072287A3 (en) Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression
MY130190A (en) Method for the preparation of 4-halo-2'- nitrobutyrophenone compounds
EP0331105A3 (en) 1,2-hydroxy phosphonates and derivatives thereof
CA2208032A1 (en) Substituted amidinonaphthyl ester derivative
WO1999065474A3 (en) Compositions for treating cartilage disease comprising certain sulfur-containing heterocyclic compounds

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 586831

Date of ref document: 19960124

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2200964

Country of ref document: CA

Ref country code: CA

Ref document number: 2200964

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995937173

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995937173

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995937173

Country of ref document: EP